New development in CAR-T cell therapy
Z Wang, Z Wu, Y Liu, W Han - Journal of hematology & oncology, 2017 - Springer
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …
Targeting the MHC ligandome by use of TCR-like antibodies
Monoclonal antibodies (mAbs) are valuable as research reagents, in diagnosis and in
therapy. Their high specificity, the ease in production, favorable biophysical properties and …
therapy. Their high specificity, the ease in production, favorable biophysical properties and …
[HTML][HTML] Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells
Little is known about the functional differences between the human skin myeloid dendritic
cell (DC) subsets, epidermal CD207+ Langerhans cells (LCs) and dermal CD14+ DCs. We …
cell (DC) subsets, epidermal CD207+ Langerhans cells (LCs) and dermal CD14+ DCs. We …
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody
T Dao, S Yan, N Veomett, D Pankov, L Zhou… - Science translational …, 2013 - science.org
The Wilms tumor 1 (WT1) oncoprotein is an intracellular, oncogenic transcription factor that
is overexpressed in a wide range of leukemias and solid cancers. RMFPNAPYL (RMF), a …
is overexpressed in a wide range of leukemias and solid cancers. RMFPNAPYL (RMF), a …
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR
E Klechevsky, AL Flamar, Y Cao… - Blood, The Journal …, 2010 - ashpublications.org
We evaluated human CD8+ T-cell responses generated by targeting antigens to dendritic
cells (DCs) through various lectin receptors. We found the immunoreceptor tyrosine-based …
cells (DCs) through various lectin receptors. We found the immunoreceptor tyrosine-based …
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
Abstract WT1 126 (RMFPNAPYL) is a human leukocyte antigen-A2 (HLA-A2)-restricted
peptide derived from Wilms tumor protein 1 (WT1), which is widely expressed in a broad …
peptide derived from Wilms tumor protein 1 (WT1), which is widely expressed in a broad …
T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
DA Scheinberg, T Dao, C Liu, S Yan - US Patent 9,074,000, 2015 - Google Patents
The present invention provides antigen binding proteins that specifically bind to Wilms'
tumor protein (WT1), including humanized, chimeric and fully human antibodies against …
tumor protein (WT1), including humanized, chimeric and fully human antibodies against …
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells
JA Weidanz, O Hawkins, B Verma… - … reviews of immunology, 2011 - Taylor & Francis
The human leukocyte antigen (HLA; also called major histocompatibility, or MHC) class I
system presents peptides that distinguish healthy from diseased cells. Therefore, the …
system presents peptides that distinguish healthy from diseased cells. Therefore, the …
Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein
HJ Belmont, S Price-Schiavi, B Liu, KF Card, H Lee… - Clinical …, 2006 - Elsevier
We previously have generated a single-chain T cell receptor-cytokine fusion protein
(264scTCR/IL-2) comprising interleukin-2 genetically linked to a soluble HLA-A2. 1 …
(264scTCR/IL-2) comprising interleukin-2 genetically linked to a soluble HLA-A2. 1 …
T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
D Scheinberg, T Dao, C Liu, S Yan - US Patent 9,540,448, 2017 - Google Patents
The present invention provides antigen binding proteins that specifically bind to Wilms'
tumor protein (WT1), including humanized, chimeric and fully human antibodies against …
tumor protein (WT1), including humanized, chimeric and fully human antibodies against …